Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 14, Issue -, Pages 823-832Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S235098
Keywords
cervical cancer; folate; pH-sensitive; carboplatin; paclitaxel; lipid-polymer hybrid nanoparticles
Categories
Ask authors/readers for more resources
Purpose: Cervical cancer is one of the most common causes of death among women globally. Combinations of cisplatin, paclitaxel, bevacizumab, carboplatin, topotecan, and gemcitabine are recommended as first-line therapies. Methods: This study focuses on the development of folate-decorated, pH-sensitive lipid-polymer hybrid nanoparticles (LPNs). Loading carboplatin (CBP) and paclitaxel (PTX), LPNs were expected to combine the therapeutic effects of CBP and PTX, thus show synergistic ability on cervical cancer. Results: FA-CBP/PTX-LPNs showed the sizes of 169.9 +/- 5.6 nm, with a narrow size distribution of 0.151 +/- 0.023. FA-CBP/PTX-LPNs exhibited pH-responsive drug release, high cellular uptake efficiency (66.7 +/- 3.1%), and prominent cell inhibition capacity (23 +/- 1.1%). In vivo tumor distribution and tumor inhibition efficiency of FA-CBP/PTX-LPNs was the highest, with no obvious body weight lost. Conclusion: High tumor distribution and remarkable antitumor efficiency obtained using in vitro as well as in vivo models further proved the FA-CBP/PTX-LPNs is a promising tool for cervical cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available